Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | IL2 | P60568 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL614892 | 0.99 | JAK2 (0.47) | JAK2JAK1TYK2MALT1MAPT | |
| SCHEMBL616462 | 0.94 | NPC1 (0.47) | JAK2JAK1TYK2MALT1MAPT | |
| Hydrochloric Acid SCHEMBL616679 | 0.93 | NPC1 (0.46) | JAK2JAK1TYK2MALT1MAPT | |
| SCHEMBL1783971 | 0.87 | TRPV1 (0.45) | MALT1MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL7920420 | 0.86 | TRPV1 (0.44) | MALT1MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL12603918 | 0.86 | MAPT (0.47) | MAPTRAB9AGAASMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL1782050 | 0.86 | TRPV1 (0.44) | MALT1MAPTRAB9AGAASMN1; SMN2 | |
| SCHEMBL614007 | 0.83 | JAK2 (0.45) | JAK2JAK1TYK2RAB9AIL2 | |
| SCHEMBL617019 | 0.83 | NPC1 (0.46) | JAK2JAK1TYK2MAPTRAB9A | |
| SCHEMBL613599 | 0.82 | IL2 (0.42) | MAPTRAB9AGAACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349841-B2 | Vinyl-aryl derivatives for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-11-18 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| WO-2010039236-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009017831-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, CXCL8 | JAK2 1719/4885JAK1 1851/4885TYK2 1057/4885 |
| US-20120040997-A9 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | JAK2 771/4885JAK1 1331/4885TYK2 317/4885 |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | JAK2 1932/4885JAK1 1686/4885TYK2 1767/4885 |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | JAK2 1932/4885JAK1 1686/4885TYK2 1767/4885 |
| US-20100292252-A1 | VINYL-ARYL DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES | MALT1, VCAM1, TSLP | JAK2 771/4885JAK1 1331/4885TYK2 317/4885 |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | JAK2 1932/4885JAK1 1686/4885TYK2 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.